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Editorial 
The results of multiple basic science and mechanistic clinical studies form a solid basis 
for a plausible pathophysiological link between obstructive sleep apnea (OSA) and 
atrial fibrillation (AF).(1) In a meta-analysis of seven prospective cohort studies 
comprising 1,087 patients, treatment of OSA by continuous positive airway pressure 
(CPAP) was associated with 40% reduction of AF recurrence after electrical 
cardioversion (ECV) or catheter ablation.(2) However, randomized controlled studies 
are lacking and this uncertainty is reflected by current international AF-guidelines, 
which recommend that it may be “reasonable” to perform CPAP treatment to reduce 
recurrent AF and optimize AF treatment results.(1) 
In the current issue of the International Journal of Cardiology, Caples et al. 
present the results of the first randomized controlled trial assessing the impact of OSA 
treatment on recurrence of persistent AF after ECV.(3) They screened 1,757 
individuals and identified 25 eligible AF patients with OSA, which were randomized to 
CPAP therapy or usual care. Despite reasonable adherence to CPAP therapy, CPAP 
could not reduce AF recurrence after ECV, which occurred in 25% of patients in the 
CPAP and the control group within one year.  
Why did this first randomized controlled trial fail to confirm the promising 
antiarrhythmic effects of CPAP treatment described in previous observational 
studies?(2) First, the number of randomized patients was much smaller than planned 
in the a priori statistical analysis plan. Thus, the study is likely underpowered to detect 
smaller antiarrhythmic CPAP effects. Second, the inclusion criterium of an apnea-
hypopnea index (AHI) >5/hour is very low and resulted in a wide range in baseline AHI 
(13.1-71.7 in the control group and 10.0-60.8 in the CPAP group) potentially 
contributing to a high variability in CPAP-related antiarrhythmic effects.(4) AF 
recurrence during follow-up was assessed by 12-lead electrocardiograms only, which 
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may have missed some self-terminating asymptomatic paroxysmal AF episodes. 
Effects on other AF treatments during follow-up (medication change, etc.) were not 
reported, CPAP adherence was not objectively assessed and it remains unclear, how 
OSA was managed when patients were not CPAP compliant. 
One important difference compared to many previous observational studies is 
the exclusion of patients with self-reported daytime sleepiness. In the general 
population, treatment of OSA is classically initiated to reduce neuro-behavioural impact 
of OSA such as daytime sleepiness. However, a lot of AF patients do not report 
excessive daytime sleepiness, irrespective of the severity of OSA, possibly because 
the burden of symptoms due to AF may often obscure and confuse those of OSA.(5) 
In these AF patients without daytime sleepiness, the main goal of OSA management 
is to ameliorate the adverse effects of OSA on the atrium and to prevent the 
progression of AF, particularly in patients were rhythm control is the primary goal. 
Interestingly, in recent randomized controlled trials of CPAP in patients with OSA and 
hypertension, CPAP reduced blood pressure most effective in OSA patients with 
daytime sleepiness.(6) The absence of antiarrhythmic effects of CPAP treatment in 
persistent AF patients without daytime sleepiness suggests, that the same may also 
account for the effects of CPAP in patients with AF and concomitant OSA. 
We also have to consider the possibility, that observational studies have largely 
overestimated the real antiarrhythmic effect of CPAP treatment in patients with AF. 
Long-term OSA has been demonstrated to result in a progressive structural remodeling 
process in the atrium which can maintain persistent AF episodes(7) and acute apnea 
associated electrophysiological changes(1) create a dynamic substrate transiently 
increasing the risk for shorter AF episodes.(8) While prevention of obstructive 
respiratory events by CPAP may reduce triggers for AF and directly translate in 
reduced susceptibility for new paroxysms of AF, the effect of OSA treatment on the 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
preexisting structural atrial arrhythmogenic substrate for persistent AF episodes is 
more difficult to predict. OSA treatment may prevent further progression of OSA-
related substrates. However, OSA is just one risk factor amongst many. Even if OSA 
is treated, this formation of proarrhythmic substrate is further promoted by inadequately 
treated or unrecognized other concomitant modifiable risk factors involving 
hypertension, obesity and metabolic syndrome. Therefore, prevention of further 
progression of OSA-related AF substrates, particularly in patients with persistent AF 
from the outset, can in the best case maintain AF risk on the same high level but will 
unlikely results in a reduction of AF recurrence after ECV (Figure, left panel). 
However, longer AF-free periods after ECV could occur if OSA-related AF substrates 
would be reversible during CPAP treatment (Figure, right panel). Whether CPAP 
treatment can reverse the atrial arrhythmogenic substrate once it has been established 
is unknown. Given the progressive natural time-course from paroxysmal to persistent 
AF, persistent AF likely represents the clinical manifestation of a more progressed AF 
substrate. While early structural changes are mainly characterized by reactive 
interstitial fibrosis, long-term remodeling is characterized by scar formation and 
increases in atrial dimensions, which may be less or not reversible, even when the 
initial stressor is removed.(1) A follow-up of 12 months may be not long enough to 
achieve structural changes which result in a reduction of AF recurrence.  
The study by Caples et al. suggests, that treatment of OSA alone without 
targeting concomitant risk factors cannot prevent recurrence of persistent AF after 
ECV. These findings therefore do not support routine CPAP treatment of OSA in 
patients with progressed persistent AF to maintain sinus rhythm. Importantly, an 
aggressive risk factor modification protocol, which included CPAP treatment of severe 
OSA as one important component, was able to reverses the type and natural 
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progression of AF.(9) Therefore, early initiation of CPAP treatment in patients with 
paroxysmal AF, a much longer treatment period and a combination with treatment of 
concomitant risk factors within a multidisciplinary integrated care approach(10) might 
be necessary to sufficiently reverse the atrial damage to the extend in which it can 
influence arrhythmia recurrence in persistent AF patients. Larger multicenter 
prospective randomized controlled trials are currently recruiting patients to further 
investigate the impact of CPAP on AF burden and AF substrate reversibility in patients 
with OSA (SLEEP-AF trial; Trial-ID: ACTRN12616000088448 and 
ACTRN12616000262404).  
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Figure 
Effect of continuous positive airway pressure (CPAP) on recurrence of persistent atrial 
fibrillation (AF) after electrical cardioversion (ECV). The progression of obstructive 
sleep apnea (OSA) related substrate (orange) and hypertension, obesity and metabolic 
syndrome related substrate (blue) are shown. Two possible scenarios: Delayed 
substrate progression (left panel) vs. Reversibility of OSA-related substrate (right 
panel).  
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